02973nas a2200313   4500008004100000020001400041024001700055245013900072210006900211260013700280300001600417490001500433520171600448653005402164653004802218653004802266653004002314653004302354653004802397653003002445653001102475653002702486653001702513100001802530700001702548700002102565700002402586856004902610       2013                        eng d  a1537-2995  awdn, 041736000aRisks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma.0 aRisks of hemolysis due to antiA and antiB caused by the transfus  aUnited StatesbBerseus,Olle. Department of Transfusion Medicine, Orebro University Hospital, Orebro, Sweden. berseus@telia.comc2013  a114S - 123S0 v53 Suppl 13 aBACKGROUND: The increasing use of fresh blood group O whole blood in acute trauma medicine makes it important to reevaluate the issue of hemolytic reactions related to the transfusion of ABO-incompatible plasma., STUDY DESIGN AND METHODS: This review summarizes and evaluates published articles and case reports concerning hemolytic reactions in connection with the transfusion of group O whole blood or blood products to nongroup O recipients., RESULTS: In 1945-1986, 15 nonmilitary publications reported hemolytic transfusion reactions with group O blood/blood products. All patients recovered except for two fatalities. Late in World War II and during the Korean and Vietnam wars and onward in Iraq and Afghanistan only "low anti-A, anti-B titer" group O whole blood has been used as universal blood. In spite of a large number of units transfused, there are no reports of hemolytic reactions. Twenty-five publications report hemolytic reactions after transfusion of group O platelets to nongroup O recipients. In all patients but one, the titer of the implicated A- or B-antibody was >100 (saline) or >400 (antiglobulin) and all cases with an infused volume of incompatible plasma <200mL were related to anti-A or anti-B antiglobulin titers >1000., CONCLUSION: In emergency lifesaving resuscitation, the risk of hemolytic transfusion reactions from transfusion of group O blood to nongroup O recipients constitutes risk that is outweighed by the benefits. A low titer of anti-A/B will minimize the risk for a hemolytic reaction, particularly if the screening is repeated after an immunization episode, e.g., blood transfusion, vaccination, or pregnancy.Copyright © 2013 American Association of Blood Banks.10a*Blood Component Transfusion/ae [Adverse Effects]10a*Blood Component Transfusion/mo [Mortality]10a*Blood Group Incompatibility/mo [Mortality]10a*Wounds and Injuries/mo [Mortality]10aABO Blood-Group System/im [Immunology]10aBlood Group Incompatibility/im [Immunology]10aHemolysis/im [Immunology]10aHumans10aPlasma/im [Immunology]10aRisk Factors1 aBerseus, Olle1 aBoman, Kjell1 aNessen, Shawn, C1 aWesterberg, Lars, A  uhttps://www.notifylibrary.org/reference/4423